Drug Type Small molecule drug |
Synonyms FXS5960, XS 04 |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 14 Jan 2025 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 14 Jan 2025 | |
| Indolent B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 14 Jan 2025 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | China | 14 Jan 2025 | |
| Mature B-Cell Neoplasm | Phase 1 | China | 14 Jan 2025 | |
| Myelodysplastic Syndromes | Phase 1 | China | 14 Jan 2025 | |
| Refractory acute myeloid leukemia | Phase 1 | China | 14 Jan 2025 | |
| Waldenstrom Macroglobulinemia | Phase 1 | China | 14 Jan 2025 | |
| Hematologic Neoplasms | Phase 1 | - | - |





